Doxycycline Suppresses Microglial Activation by Inhibiting the p38 MAPK and NF-kB Signaling Pathways - PubMed (original) (raw)
Doxycycline Suppresses Microglial Activation by Inhibiting the p38 MAPK and NF-kB Signaling Pathways
Flávia V Santa-Cecília et al. Neurotox Res. 2016 May.
Abstract
In neurodegenerative diseases, the inflammatory response is mediated by activated glial cells, mainly microglia, which are the resident immune cells of the central nervous system. Activated microglial cells release proinflammatory mediators and neurotoxic factors that are suspected to cause or exacerbate these diseases. We recently demonstrated that doxycycline protects substantia nigra dopaminergic neurons in an animal model of Parkinson's disease. This effect was associated with a reduction of microglial cell activation, which suggests that doxycycline may operate primarily as an anti-inflammatory drug. In the present study, we assessed the anti-inflammatory potential of doxycycline using lipopolysaccharide (LPS)-activated primary microglial cells in culture as a model of neuroinflammation. Doxycycline attenuated the expression of key activation markers in LPS-treated microglial cultures in a concentration-dependent manner. More specifically, doxycycline treatment lowered the expression of the microglial activation marker IBA-1 as well as the production of ROS, NO, and proinflammatory cytokines (TNF-α and IL-1β). In primary microglial cells, we also found that doxycycline inhibits LPS-induced p38 MAP kinase phosphorylation and NF-kB nuclear translocation. The present results indicate that the effect of doxycycline on LPS-induced microglial activation probably occurs via the modulation of p38 MAP kinase and NF-kB signaling pathways. These results support the idea that doxycycline may be useful in preventing or slowing the progression of PD and other neurodegenerative diseases that exhibit altered glia function.
Keywords: Cytokines; Doxycycline; Microglia; Parkinson’s disease.
Similar articles
- Mitochondrial ROS govern the LPS-induced pro-inflammatory response in microglia cells by regulating MAPK and NF-κB pathways.
Park J, Min JS, Kim B, Chae UB, Yun JW, Choi MS, Kong IK, Chang KT, Lee DS. Park J, et al. Neurosci Lett. 2015 Jan 1;584:191-6. doi: 10.1016/j.neulet.2014.10.016. Epub 2014 Oct 22. Neurosci Lett. 2015. PMID: 25459294 - A novel synthetic compound MCAP suppresses LPS-induced murine microglial activation in vitro via inhibiting NF-kB and p38 MAPK pathways.
Kim BW, More SV, Yun YS, Ko HM, Kwak JH, Lee H, Suk K, Kim IS, Choi DK. Kim BW, et al. Acta Pharmacol Sin. 2016 Mar;37(3):334-43. doi: 10.1038/aps.2015.138. Epub 2016 Feb 1. Acta Pharmacol Sin. 2016. PMID: 26838070 Free PMC article. - Microglial activation and its implications in the brain diseases.
Dheen ST, Kaur C, Ling EA. Dheen ST, et al. Curr Med Chem. 2007;14(11):1189-97. doi: 10.2174/092986707780597961. Curr Med Chem. 2007. PMID: 17504139 Review. - Neuroinflammation pathways: a general review.
Shabab T, Khanabdali R, Moghadamtousi SZ, Kadir HA, Mohan G. Shabab T, et al. Int J Neurosci. 2017 Jul;127(7):624-633. doi: 10.1080/00207454.2016.1212854. Epub 2016 Aug 9. Int J Neurosci. 2017. PMID: 27412492 Review.
Cited by
- Modulation of microglia activation by the ascorbic acid transporter SVCT2.
Marino AL, Rex TS, Harrison FE. Marino AL, et al. Brain Behav Immun. 2024 Aug;120:557-570. doi: 10.1016/j.bbi.2024.07.003. Epub 2024 Jul 6. Brain Behav Immun. 2024. PMID: 38972487 Free PMC article. - NF-κB/NLRP3 Translational Inhibition by Nanoligomer Therapy Mitigates Ethanol and Advanced Age-Related Neuroinflammation.
Anton PE, Nagpal P, Moreno J, Burchill MA, Chatterjee A, Busquet N, Mesches M, Kovacs EJ, McCullough RL. Anton PE, et al. bioRxiv [Preprint]. 2024 Feb 28:2024.02.26.582114. doi: 10.1101/2024.02.26.582114. bioRxiv. 2024. PMID: 38464118 Free PMC article. Preprint. - Doxycycline reversal of amphetamine-induced mania-like behavior is related to adjusting brain monoamine abnormalities and antioxidant effects in primary hippocampal neurons.
Chaves-Filho AJM, Soares MV, Jucá PM, Oliveira TQ, Clemente DCDS, Monteiro CEDS, Silva FGO, de Aquino PEA, Macedo DS. Chaves-Filho AJM, et al. Naunyn Schmiedebergs Arch Pharmacol. 2024 Aug;397(8):6017-6035. doi: 10.1007/s00210-024-03009-7. Epub 2024 Feb 22. Naunyn Schmiedebergs Arch Pharmacol. 2024. PMID: 38386042 - What Can Inflammation Tell Us about Therapeutic Strategies for Parkinson's Disease?
Xue J, Tao K, Wang W, Wang X. Xue J, et al. Int J Mol Sci. 2024 Jan 29;25(3):1641. doi: 10.3390/ijms25031641. Int J Mol Sci. 2024. PMID: 38338925 Free PMC article. Review. - Association between doxycycline use and long-term functioning in patients with schizophrenia.
de Witte LD, Munk Laursen T, Corcoran CM, Munk-Olsen T, Bergink V. de Witte LD, et al. Brain Behav Immun. 2024 Mar;117:66-69. doi: 10.1016/j.bbi.2023.12.036. Epub 2023 Dec 31. Brain Behav Immun. 2024. PMID: 38169245
References
- Cell Mol Life Sci. 2014 Jan;71(1):143-63 - PubMed
- Free Radic Biol Med. 2008 Sep 1;45(5):686-99 - PubMed
- Physiol Rev. 2011 Apr;91(2):461-553 - PubMed
- J Neurochem. 2005 Jul;94(2):393-404 - PubMed
- Zhonghua Yi Xue Za Zhi. 2009 May 19;89(19):1346-50 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical